Clinical Trial

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-24; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2026-03-26
Trial Details
NCT Number NCT06800963
Lead Sponsor ImmunityBio, Inc.
Conditions NMIBC
Enrollment 40 participants
Start Date 2025-10-15
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-27